Free Trial
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gelteq Limited stock logo
GELS
Gelteq
$0.52
$0.60
$0.39
▼
$2.01
$5.58M-0.411.86 million shs70,195 shs
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$0.18
$0.17
$0.14
▼
$0.42
$5.64M0.513,086 shsN/A
NSPX
Inspyr Therapeutics
$0.00
$0.00
▼
$0.07
$1.47M-17.3313.19 million shs29.64 million shs
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$1.57
$1.55
$1.16
▼
$5.50
$5.73M1.9347,074 shs15,273 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gelteq Limited stock logo
GELS
Gelteq
0.00%-4.52%-42.08%-12.78%-58.95%
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
0.00%-0.93%+1.11%+12.35%-34.30%
NSPX
Inspyr Therapeutics
0.00%0.00%0.00%0.00%0.00%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.00%-2.48%+12.95%-9.25%-67.76%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gelteq Limited stock logo
GELS
Gelteq
$0.52
$0.60
$0.39
▼
$2.01
$5.58M-0.411.86 million shs70,195 shs
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$0.18
$0.17
$0.14
▼
$0.42
$5.64M0.513,086 shsN/A
NSPX
Inspyr Therapeutics
$0.00
$0.00
▼
$0.07
$1.47M-17.3313.19 million shs29.64 million shs
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$1.57
$1.55
$1.16
▼
$5.50
$5.73M1.9347,074 shs15,273 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gelteq Limited stock logo
GELS
Gelteq
0.00%-4.52%-42.08%-12.78%-58.95%
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
0.00%-0.93%+1.11%+12.35%-34.30%
NSPX
Inspyr Therapeutics
0.00%0.00%0.00%0.00%0.00%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.00%-2.48%+12.95%-9.25%-67.76%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gelteq Limited stock logo
GELS
Gelteq
1.00
SellN/AN/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
0.00
N/AN/AN/A
NSPX
Inspyr Therapeutics
0.00
N/AN/AN/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest NSPX, GELS, INBP, and PULM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/22/2026
Gelteq Limited stock logo
GELS
Gelteq
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/14/2026
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/30/2026
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/15/2026
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 10/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gelteq Limited stock logo
GELS
Gelteq
$110K50.76N/AN/A$1.08 per share0.48
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$43.87M0.13N/AN/A$0.57 per share0.32
NSPX
Inspyr Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$7.81M0.73N/AN/A$2.45 per share0.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gelteq Limited stock logo
GELS
Gelteq
-$4.30MN/AN/AN/AN/AN/AN/AN/AN/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
-$2.84M-$0.10N/AN/AN/A-6.48%-14.78%-11.24%N/A
NSPX
Inspyr Therapeutics
-$6.30MN/AN/AN/AN/AN/AN/A-1,354.49%N/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
-$5.16M-$1.10N/AN/AN/AN/A-125.65%-95.19%11/5/2026 (Estimated)

Latest NSPX, GELS, INBP, and PULM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/25/2026Q4 2026
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
N/A-$0.04N/A-$0.04N/A$9.80 million
8/13/2026Q2 2026
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
-$2.00-$0.29+$1.71-$0.29N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Gelteq Limited stock logo
GELS
Gelteq
N/AN/AN/AN/AN/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/AN/A
NSPX
Inspyr Therapeutics
N/AN/AN/AN/AN/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gelteq Limited stock logo
GELS
Gelteq
N/AN/AN/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
N/A
3.00
1.42
NSPX
Inspyr Therapeutics
N/A
0.09
0.09
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/A
4.70
4.70

Institutional Ownership

CompanyInstitutional Ownership
Gelteq Limited stock logo
GELS
Gelteq
N/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
25.25%
NSPX
Inspyr Therapeutics
0.02%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
11.84%

Insider Ownership

CompanyInsider Ownership
Gelteq Limited stock logo
GELS
Gelteq
N/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
67.40%
NSPX
Inspyr Therapeutics
0.02%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
Gelteq Limited stock logo
GELS
Gelteq
810.71 millionN/AN/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
15330.98 million10.10 millionNot Optionable
NSPX
Inspyr Therapeutics
1543.15 millionN/ANot Optionable
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
23.65 million3.63 millionNot Optionable

Recent News About These Companies

Analyzing Urogen Pharma (NASDAQ:URGN) & Pulmatrix (NASDAQ:PULM)
September 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31055643
Pulmatrix, Inc. (NASDAQ:PULM) Stock Short Interest Rises 174.2%
September 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31055125
Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366344/0/en/eos-senolytix-to-highlight-next-generation-mitochondria-targeted-therapeutics-at-17th-world-congress-on-targeting-mitochondria.html
Pulmatrix Inc.: Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
August 13, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69303742-pulmatrix-inc-pulmatrix-announces-second-quarter-2026-financial-results-and-progress-on-merger-008.htm
Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
August 13, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/pulmatrix-announces-second-quarter-2026-financial-results-and-progress-on-merger-302850250.html
Pulmatrix Stock Short Interest Report | NASDAQ:PULM | Benzinga
July 1, 2026  |  benzinga.comhttps://www.benzinga.com/quote/PULM/short-interest
Pulmatrix Inc.: Pulmatrix Announces First Quarter 2026 Financial Results
May 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68509287-pulmatrix-inc-pulmatrix-announces-first-quarter-2026-financial-results-008.htm
Pulmatrix Inc : PULM
May 15, 2026  |  247wallst.comhttps://247wallst.com/companies/pulm/
Pulmatrix Announces First Quarter 2026 Financial Results
May 15, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/pulmatrix-announces-first-quarter-2026-financial-results-302773027.html
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
April 21, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/pulmatrix-announces-closing-of-preferred-stock-transaction-as-part-of-planned-merger-302748188.html
PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders
April 13, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260413345444/en/pulm-stock-alert-halper-sadeh-llc-is-investigating-whether-pulmatrix-inc.-is-obtaining-a-fair-price-for-its-shareholders/
Pulmatrix Inc.: Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
March 26, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-03/68048829-pulmatrix-inc-pulmatrix-and-eos-senolytix-announce-merger-agreement-to-advance-novel-mitochondrial-therapies-to-improve-healthspan-008.htm
Wave crashes on obesity drug update; Kodiak’s reboot pays dividends
March 26, 2026  |  biopharmadive.comB
Pulmatrix picked for reverse merger with anti-aging biotech weeks after Cullgen deal collapses
March 26, 2026  |  fiercebiotech.comF
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
March 26, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/pulmatrix-and-eos-senolytix-announce-merger-agreement-to-advance-novel-mitochondrial-therapies-to-improve-healthspan-302726133.html
Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout
March 2, 2026  |  fiercebiotech.comF
Pulmatrix and Cullgen Terminate Merger Agreement
March 2, 2026  |  contractpharma.comC
Gyre Therapeutics to Buy Cullgen, Which Ends Merger With Pulmatrix
March 2, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/gyre-therapeutics-to-buy-cullgen-which-ends-merger-with-pulmatrix-e48d4ee6
Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
March 2, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/pulmatrix-announces-termination-of-prior-planned-merger-and-continues-pursuit-of-alternative-merger-opportunities-302700613.html
Pulmatrix Inc.: Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results
February 26, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-02/67804153-pulmatrix-inc-pulmatrix-announces-year-end-and-fourth-quarter-2025-financial-results-008.htm

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
Stacks of coins rising on a desk beside a computer with an upward stock chart, with a blurred city skyline behind.
3 Dividend Kings to Buy While They’re Still Beaten Down
By Thomas Hughes | September 14, 2026
Fabrinet, Dycom and Qualcomm: 3 AI Fallen Angels Wall Street Just Marked Down
Fabrinet, Dycom, and Qualcomm: 3 AI Fallen Angels Wall Street Just Marked Down
By Bridget Bennett | September 14, 2026
Gelteq stock logo

Gelteq NASDAQ:GELS

$0.52 0.00 (0.00%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$0.53 +0.01 (+1.86%)
As of 10/2/2026 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.

Integrated BioPharma stock logo

Integrated BioPharma OTCMKTS:INBP

$0.18 0.00 (0.00%)
As of 10/2/2026

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

Inspyr Therapeutics OTCMKTS:NSPX

Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.

Pulmatrix stock logo

Pulmatrix NASDAQ:PULM

$1.57 0.00 (0.00%)
Closing price 10/2/2026 03:59 PM Eastern
Extended Trading
$1.52 -0.05 (-3.44%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas